Therapeutics News and Research

RSS

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells.

14 Mar 2013

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

The Scripps Research Institute and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

14 Mar 2013

USPTO issues patent to Echo Therapeutics’ Prelude SkinPrep System

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,386,027, "Skin Permeation Device For Analyte Sensing or Transdermal Drug Delivery," for the Prelude SkinPrep System, the skin permeation component of the Symphony CGM System.

12 Mar 2013

Laboratory for Molecular Biodiscovery, KU Leuven partner for €9.5M 'PharmaSea' project

KU Leuven scientist Camila Esguerra and the Laboratory for Molecular Biodiscovery are coordinating a €9.5 million, EU-funded project to collect and study marine microbes extracted from some of the ocean's deepest, most extreme - and as-yet-unexplored -biomes.

12 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

MiR-198 controls migration of skin cells necessary for wounds to close and heal

Patients with diseases such as diabetes suffer from painful wounds that take a long time to heal making them more susceptible to infections that could even lead to amputations. A*STAR's discovery paves the way for therapeutics to improve healing of such chronic wounds, which are a significant burden to patients.

11 Mar 2013

Genetic mutation that alters PIEZO1 ion channel in RBCs contributes to familial xerocytosis

A genetic mutation that alters the kinetics of an ion channel in red blood cells has been identified as the cause behind a hereditary anemia, according to a paper published this month in the Proceedings of the National Academy of Sciences by University at Buffalo scientists and colleagues.

11 Mar 2013

Wiley, BPS and ASPET partner to publish Pharmacology Research & Perspectives

John Wiley & Sons, Inc., The American Society for Pharmacology and Experimental Therapeutics (ASPET) and the British Pharmacological Society (BPS) announced today their partnership to publish the new open access, peer-reviewed journal, Pharmacology Research & Perspectives, which will open for submissions in April 2013.

8 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers at Saneron CCEL Therapeutics and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson's disease, Huntington's disease, multiple sclerosis, Alzheimer's disease as well as brain and spinal cord injury.

7 Mar 2013

UCLA scientists discover new genetic risk factor for Alzheimer's disease

Scientists at UCLA have discovered a new genetic risk factor for Alzheimer's disease by screening people's DNA and then using an advanced type of scan to visualize their brains' connections.

7 Mar 2013

Study investigates how cancer cells 'hijack' platelets

A new research study has investigated how cancer cells 'hijack' blood cells known as platelets, enabling cancer to spread around the body and promoting the growth of new tumours, it was reported today at the annual Royal College of Surgeons in Ireland (RCSI) Research Day.

7 Mar 2013

Global Blood Therapeutics, Array BioPharma partner for drug discovery research

Array BioPharma Inc. and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases.

6 Mar 2013

Wayne State receives U.S. patent allowance for vision restoration technology

Technology to restore vision through the use of a component of green algae developed by Dr. Zhou-Han Pan, professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute at Wayne State University, and licensed to RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574).

6 Mar 2013

tRNA synthetases play unexpected and critical role in cancer metastasis

Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected - and critical - additional role in cancer metastasis in a study conducted collaboratively in the labs of Karen Lounsbury, Ph.D., University of Vermont professor of pharmacology, and Christopher Francklyn, Ph.D., UVM professor of biochemistry.

5 Mar 2013